Square Pharmaceuticals PLC. announcements
313 Dhaka Stock Exchange announcements for Square Pharmaceuticals PLC. (SQURPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (21).
- Credit Rating Result
Credit Rating Information and Services PLC (CRISL) has assigned the rating of the Company as "AAA" in the long term and "ST-1" in the short term along with Stable outlook in consideration of its audited financials up to June 30, 2025; unaudited financials up to September 30, 2025 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Resumption after Record Date
Trading of the shares of the company will resume on 17.11.2025.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 8.35 for July-September 2025 as against Tk. 6.87 for July-September 2024; Consolidated NOCFPS was Tk. 7.55 for July-September 2025 as against Tk. 3.89 for July-September 2024. Consolidated NAV per share was Tk. 167.50 as on September 30, 2025 and Tk. 157.88 as on June 30, 2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 16.11.2025.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 12.11.2025 to 13.11.2025 and trading of the shares will remain suspended on record date i.e., 16.11.2025.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 12, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Dividend Declaration and Others
The Board of Directors has recommended 120% Cash Dividend for the year ended June 30, 2025. Date of AGM: 15.12.2025, Time: 10:00 AM, Venue: Virtual Platform. Record Date: 16.11.2025. The Company has also reported Consolidated EPS of Tk. 27.04, Consolidated NAV per share of Tk. 157.88 and Consolidated NOCFPS of Tk. 19.52 for the year ended June 30, 2025 as against Tk. 23.61, Tk. 142.05 and Tk. 20.90 respectively for the year ended June 30, 2024. (cont.) (Cont. News of SQURPHARMA): The Board of Directors also approved Tk. 650.00 crore for BMRE, Capital Machineries, and Lands for future expansion. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (23.10.2025) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 22, 2025 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 6.83 for January-March 2025 as against Tk. 5.55 for January-March 2024; Consolidated EPS was Tk. 21.15 for July 2024-March 2025 as against Tk. 18.24 for July 2023-March 2024. Consolidated NOCFPS was Tk. 11.90 for July 2024-March 2025 as against Tk. 17.32 for July 2023-March 2024. Consolidated NAV per share was Tk. 151.94 as on March 31, 2025 and Tk. 142.05 as on June 30, 2024. (cont.) (Cont. news of SQURPHARMA): Reasons for deviation: Due to the Eid holiday in June 2023, additional credit facilities were given to local customers, resulting in higher receivables, which were subsequently realized in July 2023. Additionally, the Company received an insurance claim related to the LVP fire incident. These two factors contributed to a spike in the NOCF per share during the period from July'23-Mar'24. In the current period, as these factors were absent, the NOCF per share has decreased. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Buy Confirmation of a Director
Mrs. Ratna Patra, one of the Directors of the Company, has further informed that she has completed her buying of 1,500,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 12.03.2025. Mr. Samuel S Chowdhury, one of the Directors of the Company, has further informed that he has completed his buying of 1,500,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 10.03.2025.
- Buy Confirmation of Managing Director
Mr. Tapan Chowdhury, the Managing Director of the Company, has further informed that he has completed his buying of 15,00,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 04.03.2025.
- Buy Declaration of a Director
Mrs. Ratna Patra, one of the Directors of the Company, has expressed her intention to buy 1,500,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
- Buy Confirmation of a Director
Mr. Anjan Chowdhury, a Director of the Company, has completed his purchase of 1,500,000 shares of the Company at prevailing market through Dhaka Stock Exchange PLC. as per declaration disseminated on 18.02.2025.
- Buy Declaration of a Director
Mr. Samuel S Chowdhury, one of the Directors of the Company, has expressed his intention to buy 1,500,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
- Buy Declaration of Managing Director
Mr. Tapan Chowdhury, Managing Director of the Company, has expressed his intention to buy 1,500,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
- Buy Declaration of Director
Mr. Anjan Chowdhury, a Director of the Company, has expressed his intention to buy 1,500,000 shares of the Company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 7.45 for October-December 2024 as against Tk. 5.92 for October-December 2023; Consolidated EPS was Tk. 14.32 for July-December 2024 as against Tk. 12.69 for July-December 2023. Consolidated NOCFPS was Tk. 8.28 for July-December 2024 as against Tk. 14.37 for July-December 2023. Consolidated NAV per share was Tk. 145.52 as on December 31, 2024 and Tk. 142.05 as on June 30, 2024.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.